Transcriptomics, proteomics and metabolomics driven biomarker discovery in COPD: an update

References

• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of COPD. [updated 2010; cited 2016 Jan 10]. Available from: www.goldcopd.org/uploads/users/files/GOLDReport_April112011.pdf
   Google Scholar
• World Health Organization. Chronic respiratory diseases. Burden of COPD. [cited 2016 Jan 10]. Available from: www.who.int/respiratory/copd/burden/en/
   Google Scholar
• Csikesz NG, Gartman EJ. New developments in the assessment of COPD: early diagnosis is key. Int J Chron Obstruct Pulmon Dis. 2014;9:277–286.
   PubMed Web of Science ®Google Scholar
• Chen H, Wang X. Significance of bioinformatics in research of chronic obstructive pulmonary disease. J Clin Bioinforma. 2011;1:35.
   PubMedGoogle Scholar
• Caudle WM, Bammler TK, Lin Y, et al. Using ‘omics’ to define pathogenesis and biomarkers of Parkinson’s disease. Expert Rev Neurother. 2010;10:925–942.
   PubMed Web of Science ®Google Scholar
• Janvilisri T. Omics-based identification of biomarkers for nasopharyngeal carcinoma. Dis Markers. 2015;2015:762128.
   PubMedGoogle Scholar
• Baggerman G, Vierstraete E, De Loof A, et al. Gel-based versus gel-free proteomics: a review. Comb Chem High Throughput Screen. 2005;8:669–677.
   PubMed Web of Science ®Google Scholar
• Griffiths WJ. Metabolomics, metabonomics and metabolite profiling. Cambridge: RSC Publishing; 2008.
   Google Scholar
• Pan Z, Raftery D. Comparing and combining NMR spectroscopy and mass spectrometry in metabolomics. Anal Bioanal Chem. 2007;387:525–527.
   PubMed Web of Science ®Google Scholar
• Soininen P, Kangas AJ, Würtz P, et al. High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism. Analyst. 2009;134:1781–1785.
   PubMed Web of Science ®Google Scholar
• Wang Z, Gerstein M, Snyder M. RNA-seq: a revolutionary tool for transcriptomics. Nat Rev Genet. 2009;10:57–63.
   PubMed Web of Science ®Google Scholar
• Comandini A, Rogliani P, Nunziata A, et al. Biomarkers of lung damage associated with tobacco smoke in induced sputum. Respir Med. 2009;103:1592–1613.
   PubMed Web of Science ®Google Scholar
• Pinto-Plata V, Toso J, Lee K, et al. Use of proteomic patterns of serum biomarkers in patients with chronic obstructive pulmonary disease: correlation with clinical parameters. Proc Am Thorac Soc. 2006;3:465–466.
   PubMedGoogle Scholar
• Wheelock CE, Goss VM, Balgoma D, et al. Application of ’omics technologies to biomarker discovery in inflammatory lung diseases. Eur Respir J. 2013;42:802–825.
   PubMed Web of Science ®Google Scholar
• Scherp P, Ku G, Coleman L, et al. Gel-based and gel-free proteomic technologies. Methods Mol Biol. 2011;702:163–190.
   PubMedGoogle Scholar
• Frantzi M, Bhat A, Latosinska A. Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development. Clin Transl Med. 2014;3:7.
   PubMedGoogle Scholar
• Chandramouli K, Qian P-Y., et al. Proteomics: challenges, techniques and possibilities to overcome biological sample complexity. Hum Genomics Proteomics. 2009;2009:1–22.
   Google Scholar
• Verrills NM, Irwin JA, He XY, et al. Identification of novel diagnostic biomarkers for asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011;183:1633–1643.
   PubMed Web of Science ®Google Scholar
• Rana GSJB, York TP, Edmiston JS, et al. Proteomic biomarkers in plasma that differentiate rapid and slow decline in lung function in adult cigarette smokers with chronic obstructive pulmonary disease (COPD). Anal Bioanal Chem. 2010;397:1809–1819.
   PubMed Web of Science ®Google Scholar
• Merali S, Barrero CA, Bowler RP, et al. Analysis of the plasma proteome in COPD: novel low abundance proteins reflect the severity of lung remodeling. Copd. 2014;11:177–189.
   PubMedGoogle Scholar
• Nicholas B, Djukanović R. Induced sputum: a window to lung pathology. Biochem Soc Trans. 2009;37:868–872.
   PubMed Web of Science ®Google Scholar
• Pelaia G, Terracciano R, Vatrella A, et al. Application of proteomics and peptidomics to COPD. Biomed Res Int. 2014;2014:1–8.
   Web of Science ®Google Scholar
• Pastor MD, Nogal A, Molina-Pinelo S, et al. Identification of proteomic signatures associated with lung cancer and COPD. J Proteomics. 2013;89:227–237.
   PubMed Web of Science ®Google Scholar
• Nicholas BL, Skipp P, Barton S, et al. Identification of lipocalin and apolipoprotein A1 as biomarkers of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;181:1049–1060.
   PubMed Web of Science ®Google Scholar
• Ohlmeier S, Mazur W, Linja-Aho A, et al. Sputum proteomics identifies elevated PIGR levels in smokers and mild-to-moderate COPD. J Proteome Res. 2012;11:599–608.
   PubMed Web of Science ®Google Scholar
• Gao J, Ohlmeier S, Nieminen P, et al. Elevated sputum BPIFB1 levels in smokers with chronic obstructive pulmonary disease: a longitudinal study. Am J Physiol Lung Cell Mol Physiol. 2015;309:L17–L26.
   Google Scholar
• Terracciano R, Preianò M, Palladino GP, et al. Peptidome profiling of induced sputum by mesoporous silica beads and MALDI-TOF MS for non-invasive biomarker discovery of chronic inflammatory lung diseases. Proteomics. 2011;11:3402–3414.
   PubMed Web of Science ®Google Scholar
• Titz B, Sewer A, Schneider T, et al. Alterations in the sputum proteome and transcriptome in smokers and early-stage COPD subjects. J Proteomics. 2015;128:306–320.
   PubMed Web of Science ®Google Scholar
• Baraniuk JN, Casado B, Pannell LK, et al. Protein networks in induced sputum from smokers and COPD patients. Int J Chron Obstruct Pulmon Dis. 2015;10:1957–1975.
   PubMed Web of Science ®Google Scholar
• Mutlu GM, Garey KW, Robbins RA, et al. Collection and analysis of exhaled breath condensate in humans. Am J Respir Crit Care Med. 2001;164:731–737.
   PubMed Web of Science ®Google Scholar
• Griese M, Noss J, von Bredow C. Protein pattern of exhaled breath condensate and saliva. Proteomics. 2002;2:690–696.
   PubMed Web of Science ®Google Scholar
• Casado B, Luisetti M, Iadarola P, et al. Advances in proteomic techniques for biomarker discovery in COPD. Expert Rev Clin Immunol. 2011;7:111–123.
   PubMed Web of Science ®Google Scholar
• Bowler RP, Ellison MC, Reisdorph N. Proteomics in pulmonary medicine. Chest. 2006;130:567–574.
   PubMed Web of Science ®Google Scholar
• Fumagalli M, Ferrari F, Luisetti M, et al. Profiling the proteome of exhaled breath condensate in healthy smokers and COPD patients by LC-MS/MS. Int J Mol Sci. 2012;13:13894–13910.
   PubMed Web of Science ®Google Scholar
• Bartlett JA, Albertolle ME, Wohlford-Lenane C, et al. Protein composition of bronchoalveolar lavage fluid and airway surface liquid from newborn pigs. Am J Physiol Lung Cell Mol Physiol. 2013;305:L256–L266.
   PubMed Web of Science ®Google Scholar
• Kipnis E, Hansen K, Sawa T, et al. Proteomic analysis of undiluted lung epithelial lining fluid. Chest. 2008;134:338–345.
   PubMed Web of Science ®Google Scholar
• Merkel D, Rist W, Seither P, et al. Proteomic study of human bronchoalveolar lavage fluids from smokers with chronic obstructive pulmonary disease by combining surface-enhanced laser desorption/ionization-mass spectrometry profiling with mass spectrometric protein identification. Proteomics. 2005;5:2972–2980.
   PubMed Web of Science ®Google Scholar
• Terracciano R, Pelaia G, Preianò M, et al. Asthma and COPD proteomics: current approaches and future directions. Proteomics Clin Appl. 2015;9:203–220.
   PubMed Web of Science ®Google Scholar
• Franciosi L, Govorukhina N, Fusetti F, et al. Proteomic analysis of human epithelial lining fluid by microfluidics-based nanoLC-MS/MS: a feasibility study. Electrophoresis. 2013;34:2683–2694.
   PubMed Web of Science ®Google Scholar
• Franciosi L, Postma DS, van den Berge M, et al. Susceptibility to COPD: differential proteomic profiling after acute smoking. PLoS One. 2014;9:e102037.
   PubMed Web of Science ®Google Scholar
• Magi B, Bargagli E, Bini L, et al. Proteome analysis of bronchoalveolar lavage in lung diseases. Proteomics. 2006;6:6354–6369.
   PubMed Web of Science ®Google Scholar
• Savino R, Paduano S, Preianò M, et al. The proteomics big challenge for biomarkers and new drug-targets discovery. Int J Mol Sci. 2012;13:13926–13948.
   PubMed Web of Science ®Google Scholar
• Tu C, Mammen MJ, Li J, et al. Large-scale, ion-current-based proteomics investigation of bronchoalveolar lavage fluid in chronic obstructive pulmonary disease patients. J Proteome Res. 2014;13:627−629.
   PubMed Web of Science ®Google Scholar
• Chen H, Wang D, Bai C, et al. Proteomics-based biomarkers in chronic obstructive pulmonary disease. J Proteome Res. 2010;9:2798–2808.
   PubMed Web of Science ®Google Scholar
• Kelsen SG, Duan X, Ji R, et al. Cigarette smoke induces an unfolded protein response in the human lung: a proteomic approach. Am J Respir Cell Mol Biol. 2008;38:541–550.
   PubMed Web of Science ®Google Scholar
• Ohlmeier S, Vuolanto M, Toljamo T, et al. Proteomics of human lung tissue identifies surfactant protein A as a marker of chronic obstructive pulmonary disease. J Proteome Res. 2008;7:5125–5132.
   PubMed Web of Science ®Google Scholar
• Lee EJ, In KH, Kim JH, et al. Proteomic analysis in lung tissue of smokers and COPD patients. Chest. 2009;135:344–352.
   PubMed Web of Science ®Google Scholar
• Alexandre BM, Charro N, Blonder J, et al. Profiling the erythrocyte membrane proteome isolated from patients diagnosed with chronic obstructive pulmonary disease. J Proteomics. 2012;76:259–269.
   PubMed Web of Science ®Google Scholar
• Ishikawa N, Ohlmeier S, Salmenkivi K, et al. Hemoglobin α and β are ubiquitous in the human lung, decline in idiopathic pulmonary fibrosis but not in COPD. Respir Res. 2010;11:123.
   PubMed Web of Science ®Google Scholar
• Ohlmeier S, Nieminen P, Gao J, et al. Lung tissue proteomics identifies elevated transglutaminase 2 levels in stable chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol. 2016;310:L1155-L1165. doi:10.1152/ajplung.00021.2016.
   PubMed Web of Science ®Google Scholar
• Nicholson JK, Lindon JC, Holmes E. ‘Metabonomics’: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica. 1999;29:1181–1189.
   PubMed Web of Science ®Google Scholar
• Lindon JC, Nicholson JK. Spectroscopic and statistical techniques for information recovery in metabonomics and metabolomics. Annu Rev Anal Chem (Palo Alto Calif). 2008;1:45–69.
   PubMed Web of Science ®Google Scholar
• Nicholson JK, Lindon JC. Systems biology: metabonomics. Nature. 2008;455:1054–1056.
   PubMed Web of Science ®Google Scholar
• Patti GJ, Yanes O, Siuzdak G. Metabolomics: the apogee of the omictriology. Nat Rev Mol Cell Biol. 2012;13:263–269.
   PubMed Web of Science ®Google Scholar
• Laurentiis GD, Paris D, Melck D, et al. Metabonomic analysis of exhaled breath condensate in adults by nuclear magnetic resonance spectroscopy. Eur Respir J. 2008;32:1175–1183.
   PubMed Web of Science ®Google Scholar
• Laurentiis GD, Paris D, Melck D, et al. Separating smoking-related diseases using NMR-based metabolomics of exhaled breath condensate. J Proteome Res. 2013;12:1502–1511.
   PubMed Web of Science ®Google Scholar
• Izquierdo-García JL, Peces-Barba G, Heili S, et al. Is NMR-based metabolomic analysis of exhaled breath condensate accurate? Eur Respir J. 2011;37:468–470.
   PubMed Web of Science ®Google Scholar
• Basanta M, Jarvis RM, Xu Y, et al. Non-invasive metabolomic analysis of breath using differential mobility spectrometry in patients with chronic obstructive pulmonary disease and healthy smokers. Analyst. 2010;135:315–320.
   PubMed Web of Science ®Google Scholar
• Basanta M, Ibrahim B, Dockry R, et al. Exhaled volatile organic compounds for phenotyping chronic obstructive pulmonary disease: a cross-sectional study. Respir Res. 2012;13:72.
   PubMed Web of Science ®Google Scholar
• Fens N, de Nijs SB, Peters S, et al. Exhaled air molecular profiling in relation to inflammatory subtype and activity in COPD. Eur Respir J. 2011;38:1301–1309.
   PubMed Web of Science ®Google Scholar
• McClay JL, Adkins DE, Isern NG, et al. (1)H nuclear magnetic resonance metabolomics analysis identifies novel urinary biomarkers for lung function. J Proteome Res. 2010;9:3083–3090.
   PubMed Web of Science ®Google Scholar
• Wang L, Tang Y, Liu S, et al. Metabonomic profiling of serum and urine by 1H NMR based spectroscopy discriminates patients with chronic obstructive pulmonary disease and healthy individuals. PLoS One. 2013;8:e65675.
   Google Scholar
• Adamko DJ, Nair P, Mayers I, et al. Metabolomic profiling of asthma and chronic obstructive pulmonary disease: a pilot study differentiating diseases. J Allergy Clin Immunol. 2015;136:571–580.
   PubMed Web of Science ®Google Scholar
• Ząbek A, Stanimirova I, Deja S, et al. Fusion of the (1)H NMR data of serum, urine and exhaled breath condensate in order to discriminate chronic obstructive pulmonary disease and obstructive sleep apnea syndrome. Metabolomics. 2015;11:1563–1574.
   PubMed Web of Science ®Google Scholar
• Ubhi BK, Riley JH, Shaw PA, et al. Metabolic profiling detects biomarkers of protein degradation in COPD patients. Eur Respir J. 2012;40:345–355.
   PubMed Web of Science ®Google Scholar
• Ubhi BK, Cheng KK, Dong J, et al. Targeted metabolomics identifies perturbations in amino acid metabolism that sub-classify patients with COPD. Mol Biosyst. 2012;8:3125–3133.
   PubMed Web of Science ®Google Scholar
• Deja S, Porebska I, Kowal A, et al. Metabolomics provide new insights on lung cancer staging and discrimination from chronic obstructive pulmonary disease. J Pharm Biomed Anal. 2014;100:369–380.
   PubMed Web of Science ®Google Scholar
• Paige M, Burdick MD, Kim S, et al. Pilot analysis of the plasma metabolite profiles associated with emphysematous chronic obstructive pulmonary disease phenotype. Biochem Biophys Res Commun. 2011;413:588–593.
   PubMed Web of Science ®Google Scholar
• Chen Q, Deeb RS, Ma Y, et al. Serum metabolite biomarkers discriminate healthy smokers from COPD smokers. PLoS One. 2015;10:e0143937.
   Google Scholar
• Telenga ED, Hoffmann RF, t’Kindt R, et al. Untargeted lipidomic analysis in chronic obstructive pulmonary disease. Uncovering sphingolipids. Am J Respir Crit Care Med. 2014;190:155–164.
   PubMed Web of Science ®Google Scholar
• Bowler RP, Jacobson S, Cruickshank C, et al. Plasma sphingolipids associated with chronic obstructive pulmonary disease phenotypes. Am J Respir Crit Care Med. 2015;191:275–284.
   PubMed Web of Science ®Google Scholar
• Malone JH, Oliver B. Microarrays, deep sequencing and the true measure of the transcriptome. BMC Biol. 2011;9:34.
   PubMed Web of Science ®Google Scholar
• Chaussabel D, Pascual V, Banchereau J. Assessing the human immune system through blood transcriptomics. BMC Biol. 2010;8:84.
   PubMed Web of Science ®Google Scholar
• Almansa R, Socias L, Sanchez-Garcia M, et al. Critical COPD respiratory illness is linked to increased transcriptomic activity of neutrophil proteases genes. BMC Res Notes. 2012;5:401.
   PubMedGoogle Scholar
• Bahr TM, Hughes GJ, Armstrong M, et al. Peripheral blood mononuclear cell gene expression in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2013;49:316–323.
   PubMed Web of Science ®Google Scholar
• Grundy S, Plumb J, Lea S, et al. Down regulation of T cell receptor expression in COPD pulmonary CD8 cells. PLoS One. 2013;8:e71629.
   PubMed Web of Science ®Google Scholar
• Roberts MEP, Higgs BW, Brohawn P, et al. CD4+ T-cell profiles and peripheral blood ex-vivo responses to T-cell directed stimulation delineate COPD phenotypes. Chronic Obstr Pulm Dis (Miami). 2015;2:268–280.
   Google Scholar
• Agler AH, Crystal RG, Mezey JG, et al. Differential expression of vitamin E and selenium-responsive genes by disease severity in chronic obstructive pulmonary disease. Copd. 2013;10:450–458.
   PubMedGoogle Scholar
• Kim WJ, Lim JH, Lee JS, et al. Comprehensive analysis of transcriptome sequencing data in the lung tissues of COPD subjects. Int J Genomics. 2015;2015:1–9.
   Google Scholar
• Faner R, Cruz T, Casserras T, et al. Network analysis of lung transcriptomics reveals a distinct B cell signature in emphysema. Am J Respir Crit Care Med. 2016;193:1242–1253.
   PubMed Web of Science ®Google Scholar
• Singh D, Fox SM, Tal-Singer R, et al. Induced sputum genes associated with spirometric and radiological disease severity in COPD ex-smokers. Thorax. 2011;66:489–495.
   PubMed Web of Science ®Google Scholar
• Kim DK, Cho MH, Hersh CP, et al. Genome-wide association analysis of blood biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186:1238–1247.
   PubMed Web of Science ®Google Scholar
• Skates SJ, Gillette MA, LaBaer J, et al. Statistical design for biospecimen cohort size in proteomics based biomarker discovery and verification studies. J Proteome Res. 2013;12:5383–5394.
   PubMed Web of Science ®Google Scholar
• Diz AP, Truebano M, Skibinski DOF. The consequences of sample pooling in proteomics: an empirical study. Electrophoresis. 2009;30:2967–2975.
   PubMed Web of Science ®Google Scholar
• Kendziorski C, Irizarry RA, Chen K-S, et al. On the utility of pooling biological samples in microarray experiments. Proc Natl Acad Sci USA. 2005;102:4252–4257.
   PubMed Web of Science ®Google Scholar
• Müller P, Parmigiani G, Robert C, et al. Optimal sample size for multiple testing. J Am Stat Assoc. 2004;99:990–100.
   Web of Science ®Google Scholar
• Tibshirani R. A simple method for assessing sample sizes in microarray experiments. BMC Bioinformatics. 2006;7:106.
   PubMed Web of Science ®Google Scholar
• Liu P, Hwanga JTG. Quick calculation for sample size while controlling false discovery rate with application to microarray analysis. Bioinformatics. 2007;23:739–746.
   PubMed Web of Science ®Google Scholar
• Lin W-J, Hsueh H-M, Chen JJ. Power and sample size estimation in microarray studies. BMC Bioinformatics. 2010;11:48.
   PubMed Web of Science ®Google Scholar
• Nyamundanda G, Gormley IC, Fan Y, et al. MetSizeR: selecting the optimal sample size for metabolomic studies using an analysis based approach. BMC Bioinformatics. 2013;14:338.
   PubMed Web of Science ®Google Scholar
• Xia J, Sinelnikov IV, Han B, et al. MetaboAnalyst 3.0––making metabolomics more meaningful. Nucleic Acids Res. 2015;43:W251–W257.
   PubMed Web of Science ®Google Scholar
• Pan W, Lin J, Le CT. How many replicates of arrays are required to detect gene expression changes in microarray experiments? A mixture model approach. Genome Biol. 2002;3:research0022.
   PubMedGoogle Scholar
• Dobbin K, Simon R. Sample size determination in microarray experiments for class comparison and prognostic classification. Biostatistics. 2005;6:27–38.
   PubMed Web of Science ®Google Scholar
• Pawitan Y, Michiels S, Koscielny S, et al. False discovery rate, sensitivity and sample size for microarray studies. Bioinformatics. 2005;21:3017–3024.
   PubMed Web of Science ®Google Scholar
• Yang MC, Yang JJ, McIndoe RA, et al. Microarray experimental design: power and sample size considerations. Physiol Genomics. 2003;16:24–28.
   PubMed Web of Science ®Google Scholar
• Qiu W, Lee MT, Whitmore GA Sizepower: sample size and power calculation in micorarray studies. R package version 1.42.0. [cited 2016 May 15]. Available from: www.bioconductor.org/packages/release/bioc/html/sizepower.html
   Google Scholar
• Dionisi HM, Harms G, Layton AC, et al. Power analysis for real-time PCR quantification of genes in activated sludge and analysis of the variability introduced by DNA extraction. Appl Environ Microbiol. 2003;69:6597–6604.
   PubMed Web of Science ®Google Scholar
• Kitchen RR, Kubista M, Tichopad A. Statistical aspects of quantitative real-time PCR experiment design. Methods. 2010;50:231–236.
   PubMed Web of Science ®Google Scholar
• Hashimoto S, Qu W, Ahsan B, et al. High resolution analysis of the 5ʹ-end transcriptome using a next generation DNA sequencer. PLoS One. 2009;4:e4108.
   Google Scholar
• Li C-I, Su P-F, Guo Y, et al. Sample size calculation for differential expression analysis of RNA-seq data under poisson distribution. Int J Comput Biol Drug Des. 2013;6:358–375.
   PubMedGoogle Scholar
• Marioni JC, Mason CE, Mane SM, et al. Rnaseq: an assessment of technical reproducibility and comparison with gene expression arrays. Genome Res. 2008;18:1509–1517.
   PubMed Web of Science ®Google Scholar
• Wang L, Feng Z, Wang X, et al. DEGseq: an R package for identifying differentially expressed genes from RNA-seq data. Bioinformatics. 2010;26:136–138.
   PubMed Web of Science ®Google Scholar
• Li J, Witten DM, Johnstone IM, et al. Normalization, testing, and false discovery rate estimation for rna-sequencing data. Biostatistics. 2011;14:1–16.
   Web of Science ®Google Scholar
• Hart SN, Therneau TM, Zhang Y, et al. Calculating sample size estimates for RNA sequencing data. J Comput Biol. 2013;20:970–978.
   PubMed Web of Science ®Google Scholar
• Haznadar M, Maruvada P, Mette E, et al. Navigating the road ahead: addressing challenges for use of metabolomics in epidemiology studies. Metabolomics. 2014;10:176–178.
   PubMed Web of Science ®Google Scholar
• Stringer KA, McKay RT, Karnovsky A, et al. metabolomics and its application to acute lung diseases. Front Immunol. 2016;7:44.
   PubMed Web of Science ®Google Scholar
• Cavailles A, Brinchault-Rabin G, Dixmier A, et al. Comorbidities of COPD. Eur Respir Rev. 2013;22:454–475.
   PubMedGoogle Scholar
• Hardin M, Silverman EK. Chronic obstructive pulmonary disease genetics: a review of the past and a look into the future. Copd. 2014;1:33–46.
   PubMedGoogle Scholar
• Kjeldgaard P, Dahl R, Løkke A, et al. Detection of COPD in a high-risk population: should the diagnostic work-up include bronchodilator reversibility testing? Int J Chron Obstruct Pulmon Dis. 2015;10:407–414.
   PubMed Web of Science ®Google Scholar
• Ning MM, Lo EH. Opportunities and challenges in omics. Transl Stroke Res. 2010;1:233–237.
   PubMed Web of Science ®Google Scholar
• Drucker E, Krapfenbauer K. Pitfalls and limitations in translation from biomarker discovery to clinical utility in predictive and personalised medicine. Epma J. 2013;4:7.
   PubMedGoogle Scholar